Q-omics provides the consensus-scored CXADRP3 profile across patient tissues and cancer cell-line models. CXADRP3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CXADRP3 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, CXADRP3 RNA expression shows 7,222 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRP, and LIHC as cancer lineages where CXADRP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXADRP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXADRP3 survival associations across molecular data types. CXADRP3 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXADRP3 RNA expression–survival associations across cancer types. High CXADRP3 expression shows unfavorable associations in KIRP, KICH, CESC, SARC, MESO and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CXADRP3 RNA expression.
This table summarizes CXADRP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CXADRP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXADRP3 shows higher tumor expression in LIHC, BRCA, LUSC, UCEC, BLCA and STAD. The LIHC box plot shows higher CXADRP3 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p < 0.001).
This table shows molecular features associated with CXADRP3 in patient tissues and cancer cell lines. In patient samples, CXADRP3 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXADRP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE.
